Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...

Globus Medical (NYSE:GMED) shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast.

Wells Fargo analyst Vik Chopra lowered the firm’s price target on Globus Medical (GMED) to $93 from $95 and keeps an Overweight rating on the ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Q4 2024 Management View CEO Daniel Scavilla highlighted record revenue of $2.519 billion for 2024, driven by $951 million in growth and a 61% increase versus the prior year. Non-GAAP EPS for the year ...

Globus Medical Inc (GMED) reports a 61% annual revenue increase and outlines strategic plans following the Nevro acquisition.

GMED earnings call for the period ending December 31, 2024.

BTIG analyst Ryan Zimmerman raised the firm’s price target on Globus Medical (GMED) to $94 from $91 and keeps a Buy rating on the shares after ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

The CEO of Globus Medical said the deal will enable the Audubon company to expand into new markets for future growth.

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...